Sillajen to launch phase 1 clinical trial in U.S. for its licensed oncology drug
SEOUL– South Korean bio firm Sillajen Inc. said Tuesday it is planning to take the first step in testing its licensed new oncology drug. Three U.S. institutions — the OHSU Knight Cancer Institute, the Mary Crowley Cancer Research and the Montefiore Medical Center — will carry out the phase 1 clinical trial for BAL0891 … Read more